Clinical Trials Browser

Active not recruiting × donafenib × 90 days × Clear all

NCT05507632 2026-06-01

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular